TG Therapeutics, Inc.
TGTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $329,004 | $233,662 | $2,785 | $6,689 |
| % Growth | 40.8% | 8,290% | -58.4% | – |
| Cost of Goods Sold | $38,486 | $14,131 | $265 | $790 |
| Gross Profit | $290,518 | $219,531 | $2,520 | $5,899 |
| % Margin | 88.3% | 94% | 90.5% | 88.2% |
| R&D Expenses | $94,291 | $76,192 | $125,352 | $222,579 |
| G&A Expenses | $154,298 | $122,706 | $95,484 | $128,090 |
| SG&A Expenses | $154,298 | $122,706 | $95,484 | $128,090 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $248,589 | $198,898 | $220,836 | $350,669 |
| Operating Income | $41,929 | $20,633 | -$218,316 | -$344,770 |
| % Margin | 12.7% | 8.8% | -7,839% | -5,154.3% |
| Other Income/Exp. Net | -$16,335 | -$7,571 | -$5,496 | -$3,331 |
| Pre-Tax Income | $25,594 | $13,062 | -$223,812 | -$348,101 |
| Tax Expense | $2,211 | $390 | $0 | $0 |
| Net Income | $23,383 | $12,672 | -$223,812 | -$348,101 |
| % Margin | 7.1% | 5.4% | -8,036.3% | -5,204.1% |
| EPS | 0.16 | 0.089 | -1.46 | -2.63 |
| % Growth | 79.2% | 106.1% | 44.5% | – |
| EPS Diluted | 0.15 | 0.085 | -1.46 | -2.63 |
| Weighted Avg Shares Out | 145,317 | 141,955 | 135,411 | 132,223 |
| Weighted Avg Shares Out Dil | 160,336 | 148,508 | 135,411 | 132,223 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $24,028 | $12,615 | $10,191 | $5,638 |
| Depreciation & Amortization | $280 | $423 | $515 | $494 |
| EBITDA | $49,902 | $26,100 | -$213,106 | -$341,969 |
| % Margin | 15.2% | 11.2% | -7,651.9% | -5,112.4% |